[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-001", "question": "A 45-year-old woman presents with progressive bilateral hearing loss, facial numbness, and ataxia. MRI reveals bilateral enhancing cerebellopontine angle masses with significant brainstem compression. Genetic testing confirms a missense mutation in the SMARCB1 gene. After maximal safe resection of the larger tumor, which management strategy offers the best long-term tumor control while preserving neurological function?", "options": ["Treatment with a selective histone deacetylase 6 (HDAC6) inhibitor", "Initiation of mTOR complex 1/2 dual inhibitor therapy", "Conformal radiotherapy targeting both lesions with dose painting", "Observation with serial MRI and consideration of bevacizumab for symptom control", "Prophylactic ventriculoperitoneal shunting followed by chemotherapy with carboplatin/vincristine"], "answer": "A", "answer_index": 0, "explanation": "The clinical scenario describes schwannomatosis due to SMARCB1 mutation. HDAC6 inhibitors have shown specific efficacy in preclinical models of SMARCB1-deficient tumors by restoring protein homeostasis and inducing apoptosis, unlike broader epigenetic modifiers. mTOR inhibitors are more relevant for NF2-related schwannomas, while radiotherapy is contraindicated in schwannomatosis due to malignant transformation risk. Bevacizumab has limited efficacy in SMARCB1-mutant tumors compared to NF2-mutant schwannomas.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible). \\nVerdict on keyed answer: No defensible answer. \\nThe item is fundamentally flawed for a clinical board exam. First, the vignette presents a contradiction: bilateral vestibular schwannomas (VS) are pathognomonic for NF2-related schwannomatosis (caused by NF2 mutations), whereas SMARCB1 mutations define SMARCB1-related schwannomatosis, which typically presents with multiple non-vestibular schwannomas and lacks bilateral VS. Second, and most critically, the question asks for the 'best management strategy' and keys an experimental therapy (HDAC6 inhibitor) based on preclinical models. In current medical practice, there is no FDA-approved HDAC6 inhibitor indicated for schwannomatosis, nor is it standard of care. Standard management involves observation, surgery, or pain management; bevacizumab is used for NF2 but not standard for SMARCB1. Testing obscure preclinical pharmacology as the 'best' clinical management is invalid. The item requires the examinee to ignore standard of care in favor of a specific research paper. \\nMinimal fix: Change the question to ask about 'potential therapeutic targets based on preclinical data' or rewrite the vignette to reflect standard NF2 management.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible). \nVerdict on keyed answer: No defensible answer. \nThe item is fundamentally flawed for a clinical board exam. First, the vignette presents a contradiction: bilateral vestibular schwannomas (VS) are pathognomonic for NF2-related schwannomatosis (caused by NF2 mutations), whereas SMARCB1 mutations define SMARCB1-related schwannomatosis, which typically presents with multiple non-vestibular schwannomas and lacks bilateral VS. Second, and most critically, the question asks for the 'best management strategy' and keys an experimental therapy (HDAC6 inhibitor) based on preclinical models. In current medical practice, there is no FDA-approved HDAC6 inhibitor indicated for schwannomatosis, nor is it standard of care. Standard management involves observation, surgery, or pain management; bevacizumab is used for NF2 but not standard for SMARCB1. Testing obscure preclinical pharmacology as the 'best' clinical management is invalid. The item requires the examinee to ignore standard of care in favor of a specific research paper. \nMinimal fix: Change the question to ask about 'potential therapeutic targets based on preclinical data' or rewrite the vignette to reflect standard NF2 management.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-002", "question": "A 68-year-old man with locally advanced pancreatic cancer involving the celiac axis undergoes stereotactic body radiotherapy (SBRT) to 40 Gy in 5 fractions. Three months later, he develops severe epigastric pain and hematemesis. Endoscopy reveals a deeply ulcerated lesion in the gastric antrum with visible vessel. Biopsy shows radiation-induced changes without malignancy. Which interventional approach is most likely to achieve durable hemostasis while minimizing the risk of gastric perforation?", "options": ["Over-the-scope clip placement with concomitant fibrin glue injection", "Hybrid argon plasma coagulation combined with topical hemostatic powder", "Selective angiography with coil embolization of the gastroduodenal artery", "Endoscopic ultrasound-guided cyanoacrylate injection into the peri-ulcer bed", "Temporary covered esophageal stent placement with nasojejunal feeding tube"], "answer": "D", "answer_index": 3, "explanation": "After high-dose SBRT, conventional endoscopic therapies often fail due to compromised tissue healing. EUS-guided cyanoacrylate injection directly targets the feeding vessel deep within the ulcer bed, creating a permanent seal without the tissue disruption caused by thermal modalities. Over-the-scope clips may not hold in friable irradiated tissue, while angiographic embolization risks non-target ischemia. Topical agents provide only temporary control in this high-flow scenario.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with a radiation-induced gastric ulcer and a visible vessel (Forrest IIa) presenting with re-bleeding. The keyed answer (D) advocates for EUS-guided cyanoacrylate injection. While this technique is described in expert literature for refractory bleeding or specific vascular lesions, it is not the standard of care for a general board examination. Standard guidelines recommend mechanical therapy (clips/OTSC) or thermal/injection therapy as first-line, with interventional radiology (angiography) as the standard rescue for failed endoscopy. \\n\\nThe stem attempts to rule out standard options: it implies Option A (OTSC) might fail due to 'friable' tissue and Option C (Angiography) might fail due to 'celiac axis involvement' (vascular access difficulty). However, these are relative, not absolute, contraindications. OTSC is FDA-approved and widely used specifically for difficult, fibrotic, or large ulcers where standard clips fail. Angiography is the standard next step despite anatomical challenges. Promoting a niche, off-label, expert-level procedure (D) over established standard-of-care options (A or C) creates a logical flaw where multiple answers are defensible (M), or the item is miskeyed (K) relative to standard guidelines. The item relies on 'mind-reading' a specific advanced endoscopy paper rather than applying consensus medical knowledge.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with a radiation-induced gastric ulcer and a visible vessel (Forrest IIa) presenting with re-bleeding. The keyed answer (D) advocates for EUS-guided cyanoacrylate injection. While this technique is described in expert literature for refractory bleeding or specific vascular lesions, it is not the standard of care for a general board examination. Standard guidelines recommend mechanical therapy (clips/OTSC) or thermal/injection therapy as first-line, with interventional radiology (angiography) as the standard rescue for failed endoscopy. \n\nThe stem attempts to rule out standard options: it implies Option A (OTSC) might fail due to 'friable' tissue and Option C (Angiography) might fail due to 'celiac axis involvement' (vascular access difficulty). However, these are relative, not absolute, contraindications. OTSC is FDA-approved and widely used specifically for difficult, fibrotic, or large ulcers where standard clips fail. Angiography is the standard next step despite anatomical challenges. Promoting a niche, off-label, expert-level procedure (D) over established standard-of-care options (A or C) creates a logical flaw where multiple answers are defensible (M), or the item is miskeyed (K) relative to standard guidelines. The item relies on 'mind-reading' a specific advanced endoscopy paper rather than applying consensus medical knowledge.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-003", "question": "A 52-year-old man undergoes right pneumonectomy for T3N2M0 non-small cell lung cancer. On postoperative day 4, he develops acute respiratory distress. Chest tube output abruptly decreases, and the mediastinum shifts toward the left on radiograph. Bronchoscopy reveals a 1.5 cm dehiscence of the bronchial stump without frank disruption. What is the most appropriate immediate management?", "options": ["Emergency rethoracotomy with direct stump revision", "Placement of a second chest tube to water seal", "Immediate bedside reopening of the incision with antibiotic irrigation", "Flexible bronchoscopic placement of an endobronchial valve in the right main bronchus", "Urgent veno-venous ECMO cannulation followed by operative repair"], "answer": "C", "answer_index": 2, "explanation": "This scenario describes a post-pneumonectomy bronchopleural fistula with impending tension physiology. Immediate bedside reopening allows mediastinal decompression and converts the situation to an open pleural cavity, preventing fatal tension. This is followed by formal operative repair after stabilization. Endobronchial valves are ineffective for large proximal dehiscences. Re-thoracotomy without decompression risks cardiovascular collapse. ECMO is reserved for refractory respiratory failure after initial stabilization.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a life-threatening tension pyopneumothorax following a right pneumonectomy, evidenced by acute respiratory distress, contralateral (left) mediastinal shift, and cessation of chest tube output (implying clogging). The bronchoscopy confirms a massive (1.5 cm) bronchopleural fistula (BPF). The immediate priority is decompression to relieve tension and prevent cardiovascular collapse. While placing a second chest tube (Option B) is a standard maneuver for pneumothorax, a 1.5 cm dehiscence represents a 'blown stump' with an air leak potentially too large for a standard chest tube to vent effectively, especially if the patient coughs or requires positive pressure ventilation. Furthermore, the existing tube has already failed. Immediate bedside reopening of the incision (Option C) is the fastest and most definitive method to equalize intrathoracic pressure (creating an open pneumothorax), preventing fatal tension and aspiration of pleural contents into the contralateral lung. This aligns with advanced thoracic surgery principles for managing large, acute post-pneumonectomy BPFs. Option A is incorrect because induction of anesthesia without prior decompression risks arrest. Options D and E are not appropriate first-line rescue maneuvers.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a life-threatening tension pyopneumothorax following a right pneumonectomy, evidenced by acute respiratory distress, contralateral (left) mediastinal shift, and cessation of chest tube output (implying clogging). The bronchoscopy confirms a massive (1.5 cm) bronchopleural fistula (BPF). The immediate priority is decompression to relieve tension and prevent cardiovascular collapse. While placing a second chest tube (Option B) is a standard maneuver for pneumothorax, a 1.5 cm dehiscence represents a 'blown stump' with an air leak potentially too large for a standard chest tube to vent effectively, especially if the patient coughs or requires positive pressure ventilation. Furthermore, the existing tube has already failed. Immediate bedside reopening of the incision (Option C) is the fastest and most definitive method to equalize intrathoracic pressure (creating an open pneumothorax), preventing fatal tension and aspiration of pleural contents into the contralateral lung. This aligns with advanced thoracic surgery principles for managing large, acute post-pneumonectomy BPFs. Option A is incorrect because induction of anesthesia without prior decompression risks arrest. Options D and E are not appropriate first-line rescue maneuvers.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-004", "question": "A 74-year-old man with a history of abdominal aortic aneurysm repair presents with acute onset of painful blue discoloration of his toes despite palpable pedal pulses. Laboratory studies show elevated creatinine kinase and acute kidney injury. Angiography demonstrates patent bypass graft but diffuse microvascular occlusion in both feet. What is the most appropriate emergent intervention?", "options": ["Immediate bilateral sympathectomy", "Systemic heparinization followed by catheter-directed thrombolysis", "High-dose corticosteroid pulse therapy", "Emergent surgical embolectomy of the tibial vessels", "Plasma exchange with albumin replacement"], "answer": "E", "answer_index": 4, "explanation": "The presentation is consistent with cholesterol embolization syndrome following aortic manipulation. Plasma exchange removes inflammatory mediators and cholesterol-laden microemboli, improving microcirculatory flow. Thrombolysis is ineffective for cholesterol crystals and increases hemorrhage risk. Sympathectomy helps vasospasm but doesn't address the embolic load. Corticosteroids may modestly reduce inflammation but don't remove emboli. Surgical embolectomy cannot access distal microvasculature.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a classic presentation of Cholesterol Embolization Syndrome (CES), also known as atheroembolic renal disease (history of aortic manipulation, blue toes with palpable pulses, AKI, elevated CK). The standard of care for CES is supportive (blood pressure control, statins, dialysis if indicated) and the cessation/avoidance of anticoagulation. The keyed answer, Plasma Exchange (Option E), is not a standard, guideline-endorsed intervention for CES. Major medical references (e.g., UpToDate, vascular surgery guidelines) often explicitly suggest *against* specific interventions like plasma exchange, corticosteroids, or anticoagulation due to lack of efficacy or potential harm, recommending supportive care instead. Thrombolysis (Option B) is generally contraindicated. Surgical embolectomy (Option D) is technically impossible for diffuse microvascular disease. Since the standard of care (supportive management) is not listed and the keyed answer represents an experimental or non-standard therapy, no option is defensible as the 'most appropriate emergent intervention.'\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a classic presentation of Cholesterol Embolization Syndrome (CES), also known as atheroembolic renal disease (history of aortic manipulation, blue toes with palpable pulses, AKI, elevated CK). The standard of care for CES is supportive (blood pressure control, statins, dialysis if indicated) and the cessation/avoidance of anticoagulation. The keyed answer, Plasma Exchange (Option E), is not a standard, guideline-endorsed intervention for CES. Major medical references (e.g., UpToDate, vascular surgery guidelines) often explicitly suggest *against* specific interventions like plasma exchange, corticosteroids, or anticoagulation due to lack of efficacy or potential harm, recommending supportive care instead. Thrombolysis (Option B) is generally contraindicated. Surgical embolectomy (Option D) is technically impossible for diffuse microvascular disease. Since the standard of care (supportive management) is not listed and the keyed answer represents an experimental or non-standard therapy, no option is defensible as the 'most appropriate emergent intervention.'", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-005", "question": "A 38-year-old woman with Crohn's disease maintained on vedolizumab presents with recurrent episodes of postprandial abdominal pain and 15-pound weight loss. CT enterography shows patent superior mesenteric artery and vein. Gastric emptying study is normal. Diagnostic laparoscopy reveals no adhesions. Which test will most likely establish the diagnosis?", "options": ["Mesenteric Doppler ultrasound with a standardized meal challenge", "Lactulose hydrogen breath test for small intestinal bacterial overgrowth", "Serum tryptase level during symptomatic episode", "Selective mesenteric angiography with vasodilator challenge", "Video capsule endoscopy with patency capsule confirmation"], "answer": "A", "answer_index": 0, "explanation": "This presentation suggests chronic mesenteric ischemia despite patent gross vasculature, possibly from vedolizumab-associated microvascular dysfunction. Provocative mesenteric Doppler can demonstrate reduced postprandial flow reserve. While bacterial overgrowth is common in Crohn's, it doesn't explain the postprandial timing. Angiography shows macrovascular disease already ruled out. Capsule endoscopy may show mucosal changes but doesn't assess flow dynamics. Tryptase would indicate mast cell disorder, which is less likely.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically invalid and relies on a hallucinated or non-existent medical association. The rationale attributes the clinical presentation to 'vedolizumab-associated microvascular dysfunction,' a condition that is not recognized in standard medical literature, guidelines, or board curricula. Vedolizumab is an alpha4-beta7 integrin antagonist used for IBD; it is not a known cause of microvascular mesenteric ischemia, nor is 'provocative mesenteric Doppler' the standard test for such a theoretical condition. In reality, a patient with Crohn's disease, postprandial pain, weight loss, and a normal CT enterography (patent vessels, no strictures) would be evaluated for active small bowel mucosal disease (missed by CT), strictures, or functional disorders. Option E (Video capsule endoscopy) is a plausible next step to rule out mucosal Crohn's recurrence not seen on CT. Option A (Doppler) is indicated for chronic mesenteric ischemia (atherosclerotic or MALS), but the stem explicitly rules out macrovascular disease via CT. Because the intended key relies on invented pathophysiology and an incorrect diagnostic pathway, no answer is defensible.\",\"medical_accuracy_score\":\"1\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically invalid and relies on a hallucinated or non-existent medical association. The rationale attributes the clinical presentation to 'vedolizumab-associated microvascular dysfunction,' a condition that is not recognized in standard medical literature, guidelines, or board curricula. Vedolizumab is an alpha4-beta7 integrin antagonist used for IBD; it is not a known cause of microvascular mesenteric ischemia, nor is 'provocative mesenteric Doppler' the standard test for such a theoretical condition. In reality, a patient with Crohn's disease, postprandial pain, weight loss, and a normal CT enterography (patent vessels, no strictures) would be evaluated for active small bowel mucosal disease (missed by CT), strictures, or functional disorders. Option E (Video capsule endoscopy) is a plausible next step to rule out mucosal Crohn's recurrence not seen on CT. Option A (Doppler) is indicated for chronic mesenteric ischemia (atherosclerotic or MALS), but the stem explicitly rules out macrovascular disease via CT. Because the intended key relies on invented pathophysiology and an incorrect diagnostic pathway, no answer is defensible.", "medical_accuracy_score": 1, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 1}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-006", "question": "A 65-year-old man presents with acute severe hematochezia. Colonoscopy reveals active bleeding from a non-ulcerated lesion in the ascending colon with a visible vessel. Biopsy shows dilated submucosal veins without evidence of vasculitis or neoplasia. CT angiography shows no arterial malformation. What is the most appropriate endoscopic therapy?", "options": ["Heater probe coagulation with high power settings", "Endoscopic band ligation of the lesion", "Injection of N-butyl-2-cyanoacrylate glue", "Placement of through-the-scope clips in a circumferential pattern", "Argon plasma coagulation with extended application time"], "answer": "B", "answer_index": 1, "explanation": "The findings are characteristic of Dieulafoy's lesion of the colon, which involves a abnormally large submucosal artery. Endoscopic band ligation is superior to thermal or clipping methods as it mechanically secures the vessel with low recurrence rates. Cyanoacrylate injection risks embolization in this location. Thermal methods may not adequately coagulate the large caliber vessel. Clips may not achieve full-thickness compression needed for this lesion type.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is logically invalid due to a direct medical contradiction in the stem. The clinical presentation (active bleeding, visible vessel, non-ulcerated) and the author's explanation point to a Dieulafoy's lesion. However, the stem states that a biopsy showed \\\"dilated submucosal veins.\\\" A Dieulafoy's lesion is pathologically defined as a caliber-persistent submucosal *artery*, not a vein. This inconsistency makes the diagnosis ambiguous (confusing Dieulafoy's with colonic varices or angiodysplasia). Furthermore, performing a biopsy on an actively bleeding vascular lesion with a visible vessel is clinically dangerous and contradicts standard safety practices, lowering the medical accuracy score. Finally, if the lesion is assumed to be a Dieulafoy's, both Endoscopic Band Ligation (Option B) and Hemoclips (Option D) are accepted first-line therapies; while some evidence favors banding for large vessels, clips are widely used, making the distinction tenuous without specifying lesion size or failure of other methods.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is logically invalid due to a direct medical contradiction in the stem. The clinical presentation (active bleeding, visible vessel, non-ulcerated) and the author's explanation point to a Dieulafoy's lesion. However, the stem states that a biopsy showed \"dilated submucosal veins.\" A Dieulafoy's lesion is pathologically defined as a caliber-persistent submucosal *artery*, not a vein. This inconsistency makes the diagnosis ambiguous (confusing Dieulafoy's with colonic varices or angiodysplasia). Furthermore, performing a biopsy on an actively bleeding vascular lesion with a visible vessel is clinically dangerous and contradicts standard safety practices, lowering the medical accuracy score. Finally, if the lesion is assumed to be a Dieulafoy's, both Endoscopic Band Ligation (Option B) and Hemoclips (Option D) are accepted first-line therapies; while some evidence favors banding for large vessels, clips are widely used, making the distinction tenuous without specifying lesion size or failure of other methods.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-007", "question": "A 55-year-old man with autosomal dominant polycystic kidney disease (ADPKD) and estimated glomerular filtration rate of 35 mL/min/1.73m² presents with acute left flank pain. CT shows a 8cm left renal cyst with hyperdense material and a fluid-debris level. Urinalysis shows 25-50 white blood cells but no bacteria. He is afebrile with normal blood pressure. What is the most appropriate management?", "options": ["Immediate initiation of ciprofloxacin", "Percutaneous drainage with cyst fluid culture", "CT-guided aspiration for cytology", "Hospital admission for intravenous ampicillin-sulbactam", "Analgesia and follow-up imaging in 4-6 weeks"], "answer": "B", "answer_index": 1, "explanation": "This presentation suggests an infected renal cyst in ADPKD, which requires drainage for both diagnosis and therapy. Cyst infections often present with minimal systemic signs in ADPKD patients. Antibiotics alone penetrate cysts poorly. Percutaneous drainage confirms the diagnosis, provides targeted therapy, and prevents sepsis. Aspiration for cytology would miss infection. Observation risks abscess formation. IV antibiotics without drainage are unlikely to eradicate the infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with ADPKD presenting with acute flank pain and a 'hyperdense' cyst with a fluid-debris level, while being afebrile. In the context of ADPKD, a 'hyperdense' cyst on CT is the classic radiologic appearance of an intracystic hemorrhage (blood has high attenuation). The presence of a fluid-debris level is also consistent with hemorrhage (hematocrit effect). Crucially, the patient is afebrile; fever is the primary distinguishing feature of cyst infection versus hemorrhage. Therefore, the clinical picture strongly supports a diagnosis of a hemorrhagic cyst. The standard of care for a stable, afebrile patient with a hemorrhagic cyst is conservative management (analgesia, rest, and hydration), which corresponds to Option E. The provided key (B) advocates for percutaneous drainage, assuming an 'infected cyst.' This is incorrect because the stem clues (hyperdensity, lack of fever) point away from infection. Furthermore, even if infection were the diagnosis, the first-line treatment for a stable patient is typically lipophilic antibiotics (e.g., fluoroquinolones, Option A), with drainage reserved for refractory cases. Promoting immediate invasive drainage for a likely self-limiting hemorrhagic cyst is inappropriate. Consequently, the item is miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with ADPKD presenting with acute flank pain and a 'hyperdense' cyst with a fluid-debris level, while being afebrile. In the context of ADPKD, a 'hyperdense' cyst on CT is the classic radiologic appearance of an intracystic hemorrhage (blood has high attenuation). The presence of a fluid-debris level is also consistent with hemorrhage (hematocrit effect). Crucially, the patient is afebrile; fever is the primary distinguishing feature of cyst infection versus hemorrhage. Therefore, the clinical picture strongly supports a diagnosis of a hemorrhagic cyst. The standard of care for a stable, afebrile patient with a hemorrhagic cyst is conservative management (analgesia, rest, and hydration), which corresponds to Option E. The provided key (B) advocates for percutaneous drainage, assuming an 'infected cyst.' This is incorrect because the stem clues (hyperdensity, lack of fever) point away from infection. Furthermore, even if infection were the diagnosis, the first-line treatment for a stable patient is typically lipophilic antibiotics (e.g., fluoroquinolones, Option A), with drainage reserved for refractory cases. Promoting immediate invasive drainage for a likely self-limiting hemorrhagic cyst is inappropriate. Consequently, the item is miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-008", "question": "A 28-year-old woman develops recurrent sinopulmonary infections and bronchiectasis. Workup reveals absent IgA, markedly reduced IgG and IgM, and absent B cells on flow cytometry. Genetic testing identifies a mutation in the λ5 surrogate light chain gene. Which specific immunological abnormality explains her infection pattern?", "options": ["Failure of heavy chain rearrangement in pre-B cells", "Defective VDJ recombination due to RAG deficiency", "Absence of the pre-B cell receptor complex signaling", "Mutation in the BLNK adapter protein preventing PLCγ activation", "Loss of BTK enzyme function disrupting B cell maturation"], "answer": "C", "answer_index": 2, "explanation": "The λ5 gene encodes part of the surrogate light chain critical for pre-B cell receptor formation. Without functional pre-BCR signaling, B cells fail to proliferate and mature at the pre-B cell stage, causing the arrested development seen here. This is distinct from Bruton's tyrosine kinase deficiency (which affects later signaling) or RAG deficiencies (which impair initial recombination). The specific λ5 mutation explains the profound B cell deficiency and hypogammaglobulinemia.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with Autosomal Recessive Agammaglobulinemia (ARA), confirmed by the specific genetic finding of a mutation in the λ5 gene (IGLL1). The λ5 protein is a component of the surrogate light chain, which pairs with the heavy chain to form the pre-B cell receptor (pre-BCR). Signaling through the pre-BCR is a critical checkpoint for B cell survival, proliferation, and maturation beyond the pre-B stage. Therefore, the absence of λ5 leads directly to the absence of pre-BCR signaling (Option C), resulting in developmental arrest and the absence of circulating B cells. Option A is incorrect because heavy chain rearrangement occurs prior to the pre-BCR checkpoint. Options B, D, and E describe distinct molecular defects (RAG, BLNK, BTK) that cause similar phenotypes but are inconsistent with the specific λ5 mutation cited in the stem. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes a patient with Autosomal Recessive Agammaglobulinemia (ARA), confirmed by the specific genetic finding of a mutation in the λ5 gene (IGLL1). The λ5 protein is a component of the surrogate light chain, which pairs with the heavy chain to form the pre-B cell receptor (pre-BCR). Signaling through the pre-BCR is a critical checkpoint for B cell survival, proliferation, and maturation beyond the pre-B stage. Therefore, the absence of λ5 leads directly to the absence of pre-BCR signaling (Option C), resulting in developmental arrest and the absence of circulating B cells. Option A is incorrect because heavy chain rearrangement occurs prior to the pre-BCR checkpoint. Options B, D, and E describe distinct molecular defects (RAG, BLNK, BTK) that cause similar phenotypes but are inconsistent with the specific λ5 mutation cited in the stem. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-009", "question": "A 42-year-old immigrant from rural Venezuela presents with progressive dyspnea and hemoptysis. Echocardiography shows severe pulmonary hypertension with right ventricular hypertrophy. Serology is positive for Strongyloides stercoralis antibodies. CT chest reveals diffuse ground-glass opacities with bronchial wall thickening. What is the most appropriate initial treatment?", "options": ["Ivermectin alone", "Ivermectin plus prednisone", "Albendazole plus diethylcarbamazine", "Praziquantel followed by ivermectin", "Thiabendazole with gradual pulmonary vasodilator therapy"], "answer": "B", "answer_index": 1, "explanation": "This presentation suggests Strongyloides hyperinfection syndrome with associated pulmonary involvement. Treatment requires both anthelminthic therapy (ivermectin) and corticosteroids to prevent lethal inflammatory response from dying larvae (paradoxical worsening). Using ivermectin alone risks fatal inflammatory reaction. Albendazole is less effective for Strongyloides. Praziquantel treats schistosomiasis, not strongyloidiasis. Vasodilators don't address the underlying parasitic infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: Miskeyed; Key B is medically dangerous. The vignette describes a patient with Strongyloides stercoralis infection (positive serology, pulmonary symptoms). The standard of care for Strongyloidiasis is Ivermectin alone (Option A). The keyed answer (B) suggests adding prednisone to 'prevent lethal inflammatory response.' This is medically incorrect and dangerous. Corticosteroids are the primary precipitating factor for Strongyloides hyperinfection syndrome; they accelerate the autoinfection cycle and increase mortality. The rationale provided conflates Strongyloidiasis with Onchocerciasis (Mazzotti reaction) or Neurocysticercosis, where steroids are used to blunt inflammation from dying parasites. In Strongyloidiasis, steroids are contraindicated unless managing a separate life-threatening condition, and even then, they are a liability, not a treatment for the infection itself. Additionally, the presence of 'severe pulmonary hypertension' is atypical for Strongyloides and suggests Schistosomiasis (also endemic in Venezuela), creating clinical dissonance, but Option A remains the only defensible management for the confirmed infection. Minimal fix: Change the key to A and correct the rationale.\",\"medical_accuracy_score\":\"1\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed; Key B is medically dangerous. The vignette describes a patient with Strongyloides stercoralis infection (positive serology, pulmonary symptoms). The standard of care for Strongyloidiasis is Ivermectin alone (Option A). The keyed answer (B) suggests adding prednisone to 'prevent lethal inflammatory response.' This is medically incorrect and dangerous. Corticosteroids are the primary precipitating factor for Strongyloides hyperinfection syndrome; they accelerate the autoinfection cycle and increase mortality. The rationale provided conflates Strongyloidiasis with Onchocerciasis (Mazzotti reaction) or Neurocysticercosis, where steroids are used to blunt inflammation from dying parasites. In Strongyloidiasis, steroids are contraindicated unless managing a separate life-threatening condition, and even then, they are a liability, not a treatment for the infection itself. Additionally, the presence of 'severe pulmonary hypertension' is atypical for Strongyloides and suggests Schistosomiasis (also endemic in Venezuela), creating clinical dissonance, but Option A remains the only defensible management for the confirmed infection. Minimal fix: Change the key to A and correct the rationale.", "medical_accuracy_score": 1, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 1}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-010", "question": "A 65-year-old liver transplant recipient on tacrolimus, mycophenolate, and prednisone presents with altered mental status and focal neurological deficits. MRI shows multiple ring-enhancing lesions with eccentric target sign. CSF PCR is positive for JC virus. What is the most appropriate management?", "options": ["Reduce immunosuppression and initiate intravenous cidofovir", "Immediate exchange transfusion to reduce tacrolimus levels", "Switch from mycophenolate to everolimus and add mirtazapine", "Administer brincidofovir and intravenous immunoglobuli", "Empiric treatment with pyrimethamine/sulfadiazine for toxoplasmosis"], "answer": "C", "answer_index": 2, "explanation": "This is progressive multifocal leukoencephalopathy (PML) in an immunocompromised host. The cornerstone is reducing immunosuppression, specifically switching from mycophenolate (which strongly inhibits T-cell function) to everolimus (which has anti-neoplastic properties and may slow PML progression). Mirtazapine has shown potential benefit by blocking 5-HT2A receptors that JC virus uses for entry. Cidofovir is ineffective against JC virus. Exchange transfusion is not indicated. Antitoxoplasma therapy would be incorrect with positive JC virus PCR.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is logically invalid due to a fatal contradiction (C) in the clinical vignette. The MRI description—\\\"multiple ring-enhancing lesions with eccentric target sign\\\"—is pathognomonic for cerebral toxoplasmosis. However, the CSF PCR is reported as positive for JC virus, which is diagnostic for Progressive Multifocal Leukoencephalopathy (PML). PML lesions are typically non-enhancing, asymmetric, subcortical white matter hyperintensities without mass effect; they do not exhibit the eccentric target sign. This creates an unsolvable conflict: the imaging findings support Option E (Toxoplasmosis treatment), while the lab findings support the intended diagnosis of PML (Option C). Furthermore, while switching to everolimus and adding mirtazapine is a proposed management strategy for PML in transplant recipients, it is not a universally accepted standard of care compared to general reduction of immunosuppression, and mirtazapine's efficacy is controversial. To fix this, the MRI description must be changed to match PML (e.g., \\\"non-enhancing white matter lesions involving subcortical U-fibers\\\").\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is logically invalid due to a fatal contradiction (C) in the clinical vignette. The MRI description—\"multiple ring-enhancing lesions with eccentric target sign\"—is pathognomonic for cerebral toxoplasmosis. However, the CSF PCR is reported as positive for JC virus, which is diagnostic for Progressive Multifocal Leukoencephalopathy (PML). PML lesions are typically non-enhancing, asymmetric, subcortical white matter hyperintensities without mass effect; they do not exhibit the eccentric target sign. This creates an unsolvable conflict: the imaging findings support Option E (Toxoplasmosis treatment), while the lab findings support the intended diagnosis of PML (Option C). Furthermore, while switching to everolimus and adding mirtazapine is a proposed management strategy for PML in transplant recipients, it is not a universally accepted standard of care compared to general reduction of immunosuppression, and mirtazapine's efficacy is controversial. To fix this, the MRI description must be changed to match PML (e.g., \"non-enhancing white matter lesions involving subcortical U-fibers\").", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-011", "question": "A 34-year-old woman presents with progressive visual field loss. MRI reveals a large suprasellar mass extending into the third ventricle with homogeneous enhancement. Endoscopic biopsy shows a mixed glial and neuronal tumor with neurocytic rosettes and perivascular pseudorosettes. Genetic analysis demonstrates BRAF V600E mutation. What is the most appropriate surgical strategy?", "options": ["Attempt gross total resection via endoscopic endonasal approach", "Subtotal resection followed by targeted BRAF inhibitor therapy", "Open craniotomy with interhemispheric transcallosal approach", "Lateral ventricle endoscopic resection with third ventriculostomy", "Stereotactic biopsy followed by conformal radiotherapy"], "answer": "B", "answer_index": 1, "explanation": "The histology describes a papillary glioneuronal tumor, a low-grade neoplasm with favorable prognosis. When BRAF V600E mutation is present, targeted therapy with BRAF inhibitors can achieve significant tumor reduction with less surgical morbidity compared to aggressive resection for this deeply located tumor. Gross total resection risks hypothalamic injury given the suprasellar location. Radiotherapy is reserved for progressive disease after medical therapy. The transcallosal approach would provide inadequate exposure for this primarily suprasellar lesion.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically incoherent due to internal contradictions in the clinical vignette. The stem describes a tumor with 'neurocytic rosettes and perivascular pseudorosettes,' which are the histologic hallmarks of Rosette-forming Glioneuronal Tumor (RGNT) or Extraventricular Neurocytoma. However, the stem assigns a BRAF V600E mutation to this tumor, which is characteristic of Ganglioglioma, Pleomorphic Xanthoastrocytoma (PXA), or Papillary Craniopharyngioma, but not RGNT (typically FGFR1-mutated) or Neurocytoma. The rationale incorrectly identifies the tumor as a 'Papillary Glioneuronal Tumor' (PGNT), an entity actually defined by SLC44A1-PRKCA fusions, not BRAF mutations or neurocytic rosettes. Furthermore, while BRAF inhibitors are used for BRAF-mutated CNS tumors, they are typically reserved for recurrent, progressive, or unresectable disease rather than as immediate adjuvant therapy following subtotal resection for a newly diagnosed low-grade glioneuronal tumor (where observation is standard). The conflation of three distinct tumor types (RGNT histology, Ganglioglioma/Craniopharyngioma genetics, PGNT name) makes the diagnosis impossible and the 'best' management strategy undefinable.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically incoherent due to internal contradictions in the clinical vignette. The stem describes a tumor with 'neurocytic rosettes and perivascular pseudorosettes,' which are the histologic hallmarks of Rosette-forming Glioneuronal Tumor (RGNT) or Extraventricular Neurocytoma. However, the stem assigns a BRAF V600E mutation to this tumor, which is characteristic of Ganglioglioma, Pleomorphic Xanthoastrocytoma (PXA), or Papillary Craniopharyngioma, but not RGNT (typically FGFR1-mutated) or Neurocytoma. The rationale incorrectly identifies the tumor as a 'Papillary Glioneuronal Tumor' (PGNT), an entity actually defined by SLC44A1-PRKCA fusions, not BRAF mutations or neurocytic rosettes. Furthermore, while BRAF inhibitors are used for BRAF-mutated CNS tumors, they are typically reserved for recurrent, progressive, or unresectable disease rather than as immediate adjuvant therapy following subtotal resection for a newly diagnosed low-grade glioneuronal tumor (where observation is standard). The conflation of three distinct tumor types (RGNT histology, Ganglioglioma/Craniopharyngioma genetics, PGNT name) makes the diagnosis impossible and the 'best' management strategy undefinable.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-012", "question": "A 72-year-old man with metastatic castration-resistant prostate cancer to bones undergoes palliative radiotherapy to a symptomatic lumbar spine metastasis (8 Gy × 1). Two weeks later, he develops sudden onset bilateral lower extremity weakness and numbness. MRI shows new T2 hyperintensity in the thoracolumbar cord extending beyond the radiation field. What is the most likely diagnosis?", "options": ["Radiation myelopathy", "Leptomeningeal carcinomatosis", "Paraneoplastic myelitis associated with anti-amphiphysin antibodies", "Spinal cord infarction from tumor embolus", "Subacute combined degeneration from B12 deficiency"], "answer": "C", "answer_index": 2, "explanation": "This presentation describes a paraneometric myelitis triggered by radiation-induced tumor cell death releasing antigens, not direct radiation toxicity (which occurs after longer latency and respects radiation fields). Prostate cancer is associated with anti-amphiphysin antibodies that can cause myelitis. Leptomeningeal disease would show enhancement on MRI. Radiation myelopathy typically presents 6-24 months post-treatment. Cord infarction would have acute dramatic onset rather than subacute progression.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: C (Contradiction). Verdict: No defensible answer due to internal inconsistency. The stem describes 'sudden onset' bilateral weakness, which is the classic clinical discriminator for vascular events (e.g., spinal cord infarction). However, the keyed answer is C (Paraneoplastic myelitis), a condition characterized by subacute progression (days to weeks). The provided rationale explicitly contradicts the stem, arguing that infarction is incorrect because it would present with 'acute dramatic onset' rather than 'subacute progression,' despite the stem clearly stating 'sudden onset.' Furthermore, while paraneoplastic syndromes can occur with prostate cancer, anti-amphiphysin antibodies are strongly associated with breast cancer and small cell lung cancer (Stiff-Person Syndrome), making this an obscure and potentially misleading association for a general board exam. Option D fits the temporal profile ('sudden') best but specifies a rare mechanism (tumor embolus). The contradiction between the clinical descriptors in the stem and the intended diagnosis makes the item logically invalid. Minimal fix: Change 'sudden onset' to 'progressive weakness over 3 days' and ensure the antibody association aligns with standard teaching or provide stronger clues.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction). Verdict: No defensible answer due to internal inconsistency. The stem describes 'sudden onset' bilateral weakness, which is the classic clinical discriminator for vascular events (e.g., spinal cord infarction). However, the keyed answer is C (Paraneoplastic myelitis), a condition characterized by subacute progression (days to weeks). The provided rationale explicitly contradicts the stem, arguing that infarction is incorrect because it would present with 'acute dramatic onset' rather than 'subacute progression,' despite the stem clearly stating 'sudden onset.' Furthermore, while paraneoplastic syndromes can occur with prostate cancer, anti-amphiphysin antibodies are strongly associated with breast cancer and small cell lung cancer (Stiff-Person Syndrome), making this an obscure and potentially misleading association for a general board exam. Option D fits the temporal profile ('sudden') best but specifies a rare mechanism (tumor embolus). The contradiction between the clinical descriptors in the stem and the intended diagnosis makes the item logically invalid. Minimal fix: Change 'sudden onset' to 'progressive weakness over 3 days' and ensure the antibody association aligns with standard teaching or provide stronger clues.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-013", "question": "A 58-year-old man undergoes left lower lobectomy for stage IIA NSCLC. On postoperative day 2, he develops productive cough and low-grade fever. Chest tube output increases to 450 mL/day of serosanguinous fluid. Fluid analysis shows pH 7.25, glucose 45 mg/dL, LDH 485 U/L. What is the most appropriate management?", "options": ["Insertion of a second chest tube", "Immediate return to operating room for exploration", "Initiation of broad-spectrum antibiotics alone", "Video-assisted thoracoscopic drainage and pleural irrigation", "Observation with repeat chest radiograph in 24 hours"], "answer": "D", "answer_index": 3, "explanation": "The fluid characteristics (low pH, low glucose, elevated LDH) indicate an early empyema or complicated parapneumonic effusion. VATS allows direct visualization, breakdown of loculations, thorough irrigation, and precise tube placement. A second chest tube may not address localized infection. Reoperation is premature without attempted minimally invasive drainage. Antibiotics alone won't drain the infected space. Observation risks progression to fibrinopurulent stage.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is underspecified, preventing the selection of a unique best answer. The choice between initiating antibiotics (C) and proceeding to VATS (D) depends entirely on imaging findings (CXR or CT) which are not provided. Specifically, one must know if the pleural space is loculated or if the lung is fully expanded. The patient already has a chest tube draining 450 mL/day (indicating patency), and the pleural fluid pH (7.25) is above the typical threshold (<7.20) that mandates surgical intervention for complicated parapneumonic effusion. While the glucose is low (45 mg/dL), this can occur in serosanguinous fluid or complicated effusions. On postoperative day 2, fever and productive cough strongly suggest pneumonia; if the lung is expanded and the tube is functioning, antibiotics (C) are the standard of care. VATS (D) is indicated only if there are undrained loculations or trapped lung. Without imaging data confirming loculation, jumping to VATS is an aggressive assumption, making the item logically invalid.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is underspecified, preventing the selection of a unique best answer. The choice between initiating antibiotics (C) and proceeding to VATS (D) depends entirely on imaging findings (CXR or CT) which are not provided. Specifically, one must know if the pleural space is loculated or if the lung is fully expanded. The patient already has a chest tube draining 450 mL/day (indicating patency), and the pleural fluid pH (7.25) is above the typical threshold (<7.20) that mandates surgical intervention for complicated parapneumonic effusion. While the glucose is low (45 mg/dL), this can occur in serosanguinous fluid or complicated effusions. On postoperative day 2, fever and productive cough strongly suggest pneumonia; if the lung is expanded and the tube is functioning, antibiotics (C) are the standard of care. VATS (D) is indicated only if there are undrained loculations or trapped lung. Without imaging data confirming loculation, jumping to VATS is an aggressive assumption, making the item logically invalid.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-014", "question": "A 68-year-old woman with a history of thoracic endovascular aortic repair (TEVAR) for descending aortic aneurysm presents with hoarseness and dysphagia. Barium swallow shows external compression of the esophagus without mucosal abnormality. Which management strategy addresses the most likely etiology while minimizing procedural risk?", "options": ["Revision TEVAR with proximal extension", "Direct laryngoscopy with vocal cord medialization", "Esophageal stent placement", "CT angiography of the chest with 3D reconstruction", "Open surgical aneurysm repair via left thoracotomy"], "answer": "D", "answer_index": 3, "explanation": "Hoarseness suggests recurrent laryngeal nerve palsy, and dysphagia indicates mechanical compression-findings consistent with a newly enlarging aortic aneurysm at the TEVAR landing zone causing mass effect. CTA provides definitive evaluation of aneurysm size and relationship to adjacent structures. Endoscopy may show compression but cannot characterize the extracesophageal cause. Revision TEVAR or open repair would be premature without demonstrating aneurysm growth. Mere observation misses the opportunity for timely intervention if expansion is confirmed.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with symptoms of mediastinal mass effect (hoarseness, dysphagia) following TEVAR, highly suggestive of aneurysm expansion (likely due to endoleak) or migration. The standard of care requires immediate anatomical imaging to define the underlying pathology before any intervention. CT Angiography (Option D) is the gold standard for evaluating post-TEVAR complications and is the necessary first step in management. Options A (Revision TEVAR) and E (Open repair) are definitive treatments, but selecting between them is impossible without the anatomical information provided by the CTA; proceeding directly to surgery without imaging would be malpractice. Option C (Stenting) is contraindicated without ruling out aortoesophageal fistula and does not treat the extrinsic compression source. Option B is symptomatic only. Although the phrase 'addresses the etiology' is slightly imprecise (as CTA diagnoses rather than treats), in the context of 'management strategy' and 'minimizing risk,' establishing a diagnosis is the only logical and safe first step. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with symptoms of mediastinal mass effect (hoarseness, dysphagia) following TEVAR, highly suggestive of aneurysm expansion (likely due to endoleak) or migration. The standard of care requires immediate anatomical imaging to define the underlying pathology before any intervention. CT Angiography (Option D) is the gold standard for evaluating post-TEVAR complications and is the necessary first step in management. Options A (Revision TEVAR) and E (Open repair) are definitive treatments, but selecting between them is impossible without the anatomical information provided by the CTA; proceeding directly to surgery without imaging would be malpractice. Option C (Stenting) is contraindicated without ruling out aortoesophageal fistula and does not treat the extrinsic compression source. Option B is symptomatic only. Although the phrase 'addresses the etiology' is slightly imprecise (as CTA diagnoses rather than treats), in the context of 'management strategy' and 'minimizing risk,' establishing a diagnosis is the only logical and safe first step. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-015", "question": "A 47-year-old woman with situs inversus totalis presents with recurrent episodes of acute pancreatitis. MRCP shows pancreas divisum with Santorinicole in the dorsal duct. Previous minor papilla sphincterotomy provided only temporary relief. What is the most appropriate definitive management?", "options": ["Total pancreatectomy with islet autotransplantation", "Long-term pancreatic stent placement across the minor papilla", "Endoscopic ultrasound-guided gastroenterostomy creation", "Surgical dorsal duct jejunostomy (Puestow procedure)", "Repeat ERCP with extended sphincterotomy and stricture dilation"], "answer": "A", "answer_index": 0, "explanation": "In the setting of situs inversus with complex pancreatic duct anatomy (Santorinicole) and failed sphincterotomy, TP-IAT offers the only definitive solution for recurrent pancreatitis while preserving endocrine function. The anomalous anatomy makes standard drainage procedures (Puestow) technically challenging and less effective. Long-term stenting leads to ductal changes and strictures. EUS-guided drainage would not address the underlying drainage impairment from the Santorinicole.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item contains a significant medical error and relies on flawed logic. First, the term \\\"Santorinicole\\\" is a hallucination or severe typo (likely intended to be \\\"Santorinicele,\\\" a cystic dilation of the dorsal duct). Second, the keyed answer (A, Total pancreatectomy with islet autotransplantation) is an overly aggressive, end-stage management option for recurrent acute pancreatitis (RAP). TP-IAT is typically reserved for established chronic pancreatitis with intractable pain or hereditary pancreatitis after other options fail. Third, the rationale that situs inversus precludes a Puestow procedure (Option D) is medically incorrect; while technically challenging, situs inversus is not a contraindication for drainage procedures. Option D would be the standard definitive surgical management if the pancreatic duct is dilated, but the stem fails to specify duct diameter (Underspecified). Consequently, the item forces a radical, non-standard treatment based on a non-existent anatomical term and false surgical limitations. No option is defensible as the 'best' answer under standard medical guidelines.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item contains a significant medical error and relies on flawed logic. First, the term \"Santorinicole\" is a hallucination or severe typo (likely intended to be \"Santorinicele,\" a cystic dilation of the dorsal duct). Second, the keyed answer (A, Total pancreatectomy with islet autotransplantation) is an overly aggressive, end-stage management option for recurrent acute pancreatitis (RAP). TP-IAT is typically reserved for established chronic pancreatitis with intractable pain or hereditary pancreatitis after other options fail. Third, the rationale that situs inversus precludes a Puestow procedure (Option D) is medically incorrect; while technically challenging, situs inversus is not a contraindication for drainage procedures. Option D would be the standard definitive surgical management if the pancreatic duct is dilated, but the stem fails to specify duct diameter (Underspecified). Consequently, the item forces a radical, non-standard treatment based on a non-existent anatomical term and false surgical limitations. No option is defensible as the 'best' answer under standard medical guidelines.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-016", "question": "A 52-year-old man with alcohol-related cirrhosis presents with acute upper GI bleeding. During emergent endoscopy, active spurting is seen from a large duodenal ulcer in the posterior bulb. After epinephrine injection and placement of two through-the-scope clips, bleeding continues. The following day, he develops fever and severe abdominal pain. CT shows retroperitoneal air and fluid tracking along the right psoas muscle. What is the most appropriate management?", "options": ["Angiographic embolization of the gastroduodenal artery", "Emergency laparotomy with duodenal diversion", "Percutaneous drainage of the retroperitoneal collection", "Repeat endoscopy with over-the-scope clip placement", "IV antibiotics and serial abdominal exams"], "answer": "B", "answer_index": 1, "explanation": "This scenario describes a posterior duodenal ulcer perforation into the retroperitoneum following endoscopic intervention. Given the ongoing bleeding and established contamination, definitive surgical management with duodenal diversion (e.g., Graham patch closure with gastrodujunostomy) is required. Angioembolization would address bleeding but not the perforation. Percutaneous drainage cannot control the duodenal leak. Repeat endoscopy is contraindicated with known perforation. Antibiotics alone would lead to uncontrolled sepsis.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with a posterior duodenal ulcer who has failed endoscopic hemostasis and now presents with signs of retroperitoneal perforation (retroperitoneal air/fluid) and sepsis (fever, severe pain). The timeline contains a physiological inaccuracy: 'active spurting' that 'continues' would typically result in exsanguination or immediate intervention, rather than the patient presenting 'the following day.' However, the clinical snapshot at the time of decision-making (sepsis + retroperitoneal perforation) is unambiguous. A posterior perforation with sepsis requires surgical management to control the leak and the vessel. Angiographic embolization (A) addresses the bleeding but fails to manage the septic perforation. Percutaneous drainage (C) is insufficient for an acute perforation with severe symptoms. Repeat endoscopy (D) is contraindicated in the setting of perforation. Option B (Laparotomy with duodenal diversion) is the only choice that addresses the life-threatening perforation and allows for definitive control of the bleeding vessel in a difficult anatomical location.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with a posterior duodenal ulcer who has failed endoscopic hemostasis and now presents with signs of retroperitoneal perforation (retroperitoneal air/fluid) and sepsis (fever, severe pain). The timeline contains a physiological inaccuracy: 'active spurting' that 'continues' would typically result in exsanguination or immediate intervention, rather than the patient presenting 'the following day.' However, the clinical snapshot at the time of decision-making (sepsis + retroperitoneal perforation) is unambiguous. A posterior perforation with sepsis requires surgical management to control the leak and the vessel. Angiographic embolization (A) addresses the bleeding but fails to manage the septic perforation. Percutaneous drainage (C) is insufficient for an acute perforation with severe symptoms. Repeat endoscopy (D) is contraindicated in the setting of perforation. Option B (Laparotomy with duodenal diversion) is the only choice that addresses the life-threatening perforation and allows for definitive control of the bleeding vessel in a difficult anatomical location.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-017", "question": "A 35-year-old woman with tuberous sclerosis complex develops rapidly progressive renal insufficiency. Imaging shows massively enlarged kidneys with innumerable angiomyolipomas, the largest measuring 8 cm. What is the most appropriate intervention to preserve renal function?", "options": ["Selective arterial embolization of the dominant tumors", "Initiation of everolimus therapy", "Bilateral nephrectomy with dialysis initiation", "Cryoablation of the largest angiomyolipomas", "Radical nephrectomy of the more affected kidney"], "answer": "B", "answer_index": 1, "explanation": "In TSC with diffuse angiomyolipomatosis causing renal failure, everolimus (an mTOR inhibitor) is first-line therapy as it targets the underlying pathophysiology, can reduce tumor size by over 50%, and preserves renal function better than procedural interventions. Embolization or ablation would be impractical for innumerable tumors and could accelerate renal decline. Nephrectomy should be avoided unless absolutely necessary for hemorrhage control. Everolimus addresses the systemic nature of TSC renal involvement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best. The vignette describes a patient with Tuberous Sclerosis Complex (TSC) and diffuse renal angiomyolipomatosis causing renal insufficiency. The clinical goal is to preserve renal function. Guidelines (e.g., International TSC Consensus, EXIST-2 trial) recommend mTOR inhibitors (Everolimus) as the first-line treatment for asymptomatic growing angiomyolipomas or those causing mass effect, specifically to reduce tumor volume and stabilize renal function without surgical morbidity. Procedural options like embolization (A) or ablation (D) are technically impractical for 'innumerable' diffuse lesions and carry significant risks of parenchymal loss. Nephrectomy (C, E) would precipitate immediate end-stage renal disease, directly contradicting the goal of preservation. While 'rapidly progressive' insufficiency is an alarming feature that might suggest acute complications, Everolimus remains the only option among the choices that addresses the underlying pathology while attempting to spare nephrons.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. The vignette describes a patient with Tuberous Sclerosis Complex (TSC) and diffuse renal angiomyolipomatosis causing renal insufficiency. The clinical goal is to preserve renal function. Guidelines (e.g., International TSC Consensus, EXIST-2 trial) recommend mTOR inhibitors (Everolimus) as the first-line treatment for asymptomatic growing angiomyolipomas or those causing mass effect, specifically to reduce tumor volume and stabilize renal function without surgical morbidity. Procedural options like embolization (A) or ablation (D) are technically impractical for 'innumerable' diffuse lesions and carry significant risks of parenchymal loss. Nephrectomy (C, E) would precipitate immediate end-stage renal disease, directly contradicting the goal of preservation. While 'rapidly progressive' insufficiency is an alarming feature that might suggest acute complications, Everolimus remains the only option among the choices that addresses the underlying pathology while attempting to spare nephrons.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-018", "question": "A 6-month-old boy presents with recurrent sinopulmonary infections, failure to thrive, and absent lymph nodes on examination. Flow cytometry shows profoundly decreased T cells with normal B cell numbers. Mitogen proliferation assays show no response. Genetic testing reveals a missense mutation in the ORAI1 gene. What specific immunologic defect is present?", "options": ["Defective thymic epithelial development", "Impaired VDJ recombination in T cell receptors", "Absence of stores operated calcium entry", "Mutation in the ζ-chain-associated protein kinase", "Adenosine deaminase deficiency with metabolic toxicity"], "answer": "C", "answer_index": 2, "explanation": "ORAI1 encodes a calcium release-activated calcium channel essential for store-operated calcium entry (SOCE), which is critical for T cell activation, cytokine production, and immune function. Without SOCE, T cells cannot properly activate despite normal development, explaining the severe combined immunodeficiency presentation with normal lymphocyte numbers but functional impairment. This is distinct from recombination defects (RAG, Artemis) or metabolic deficiencies (ADA). The ORAI1 mutation specifically disrupts calcium signaling after T cell receptor engagement.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best\\n\\nThe item tests the mechanism of ORAI1 deficiency. The keyed answer (C) correctly identifies that ORAI1 encodes the pore-forming subunit of the CRAC channel, which is essential for Store-Operated Calcium Entry (SOCE). The explicit mention of the ORAI1 mutation in the stem makes C the unique best answer, as the other options describe mechanisms for different immunodeficiencies (DiGeorge, RAG, ZAP-70, ADA).\\n\\nHowever, the item contains a significant medical inaccuracy regarding the clinical phenotype. ORAI1 deficiency (CRAC channelopathy) is classically distinguished from other forms of SCID by the presence of normal (or elevated) T and B cell counts and often palpable lymph nodes, despite profound functional impairment (anergy). The vignette describes \\\"profoundly decreased T cells\\\" and \\\"absent lymph nodes,\\\" which is the phenotype of X-linked (gamma-c) or JAK3 SCID, not ORAI1 deficiency. While this internal contradiction between phenotype and genotype is flawed, the explicit genetic diagnosis allows the examinee to select the correct mechanism (SOCE) without ambiguity, as no option corresponds to the X-linked SCID phenotype described.\\n\\nMinimal fix: Change the stem to read \\\"normal T and B cell numbers\\\" and \\\"palpable lymph nodes\\\" to align the phenotype with the ORAI1 mutation.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best\n\nThe item tests the mechanism of ORAI1 deficiency. The keyed answer (C) correctly identifies that ORAI1 encodes the pore-forming subunit of the CRAC channel, which is essential for Store-Operated Calcium Entry (SOCE). The explicit mention of the ORAI1 mutation in the stem makes C the unique best answer, as the other options describe mechanisms for different immunodeficiencies (DiGeorge, RAG, ZAP-70, ADA).\n\nHowever, the item contains a significant medical inaccuracy regarding the clinical phenotype. ORAI1 deficiency (CRAC channelopathy) is classically distinguished from other forms of SCID by the presence of normal (or elevated) T and B cell counts and often palpable lymph nodes, despite profound functional impairment (anergy). The vignette describes \"profoundly decreased T cells\" and \"absent lymph nodes,\" which is the phenotype of X-linked (gamma-c) or JAK3 SCID, not ORAI1 deficiency. While this internal contradiction between phenotype and genotype is flawed, the explicit genetic diagnosis allows the examinee to select the correct mechanism (SOCE) without ambiguity, as no option corresponds to the X-linked SCID phenotype described.\n\nMinimal fix: Change the stem to read \"normal T and B cell numbers\" and \"palpable lymph nodes\" to align the phenotype with the ORAI1 mutation.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-019", "question": "A 30-year-old missionary presents with a slowly enlarging scalp lesion after returning from Bolivia. biopsy demonstrates lobulated granulomatous inflammation with rare 5-7 μm budding yeast. Culture on brain-heart infusion agar at 25°C shows cream-colored colonies that convert to yeast form at 37°C. What is the most appropriate antifungal therapy?", "options": ["Itraconazole for 6-12 months", "Amphotericin B lipid complex followed by itraconazole", "Voriconazole indefinitely", "Posaconazole with therapeutic drug monitoring", "Fluconazole for 3-6 months"], "answer": "A", "answer_index": 0, "explanation": "The presentation describes cutaneous granulomas caused by Paracoccidioides brasiliensis, endemic to Latin America. Itraconazole is first-line for non-severe disease, with 6-12 months treatment typically achieving cure. Amphotericin B is reserved for severe disseminated disease. Voriconazole has variable activity against Paracoccidioides. Fluconazole is less effective due to higher relapse rates. The dimorphic growth pattern and geographic history are classic for this infection.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with a chronic cutaneous fungal infection acquired in Bolivia. The culture confirms a dimorphic fungus (mold at 25°C, yeast at 37°C). While the yeast size (5-7 μm) is somewhat smaller than the classic large 'pilot's wheel' forms of *Paracoccidioides brasiliensis* (often 10-30 μm), the geographic history and clinical presentation are highly suggestive of Paracoccidioidomycosis. Regardless of whether the organism is *Paracoccidioides*, *Sporothrix*, or *Blastomyces*, Itraconazole is the standard first-line therapy for mild-to-moderate localized cutaneous disease. Amphotericin B (Option B) is reserved for severe, disseminated, or life-threatening infections. Fluconazole (Option E) is associated with higher relapse rates in endemic mycoses compared to Itraconazole. Thus, Option A is the unique best answer supported by standard infectious disease guidelines. The item is logically valid.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with a chronic cutaneous fungal infection acquired in Bolivia. The culture confirms a dimorphic fungus (mold at 25°C, yeast at 37°C). While the yeast size (5-7 μm) is somewhat smaller than the classic large 'pilot's wheel' forms of *Paracoccidioides brasiliensis* (often 10-30 μm), the geographic history and clinical presentation are highly suggestive of Paracoccidioidomycosis. Regardless of whether the organism is *Paracoccidioides*, *Sporothrix*, or *Blastomyces*, Itraconazole is the standard first-line therapy for mild-to-moderate localized cutaneous disease. Amphotericin B (Option B) is reserved for severe, disseminated, or life-threatening infections. Fluconazole (Option E) is associated with higher relapse rates in endemic mycoses compared to Itraconazole. Thus, Option A is the unique best answer supported by standard infectious disease guidelines. The item is logically valid.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed130", "question_id": "20251216T183904770Z_deepseek-v3.2_seed130-020", "question": "A 42-year-old woman with HIV (CD4 180 cells/μL, viral load undetectable on ART) presents with 2 weeks of progressive neurological decline. MRI shows multiple ring-enhancing lesions with minimal edema. CSF PCR is negative for JC virus, toxoplasma, and CMV. Brain biopsy reveals necrotizing encephalitis with bizarre astrocytes and intranuclear viral inclusions. What is the most appropriate treatment?", "options": ["High-dose ganciclovir", "Intravenous foscarnet", "Artemisinin combination therapy", "Pyrimethamine plus sulfadiazine", "Cidofovir with probenecid"], "answer": "B", "answer_index": 1, "explanation": "The histopathological findings are characteristic of cytomegalovirus encephalitis, which can present with atypical MRI findings in immunocompromised hosts. Foscarnet is preferred over ganciclovir in this scenario because CMV encephalitis in HIV patients often occurs despite undetectable plasma viral loads, suggesting possible ganciclovir resistance or poor CNS penetration. Foscarnet has different mechanisms of action and better CNS penetration. The negative CSF PCR does not rule out CMV encephalitis due to low viral loads. Arteminsinin and anti-toxoplasma therapies would not address CMV.", "generator_model": "deepseek-v3.2", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically inaccurate and logically invalid due to contradictory clinical and histopathological findings. The vignette describes a patient with CD4 180 cells/μL (typically too high for CMV encephalitis, which usually occurs at <50 cells/μL) and 'bizarre astrocytes' on biopsy. 'Bizarre astrocytes' are the classic histopathological hallmark of Progressive Multifocal Leukoencephalopathy (PML), not CMV. While 'intranuclear inclusions' occur in both, the specific mention of bizarre astrocytes strongly points to PML. However, the MRI showing 'ring-enhancing lesions' is atypical for both PML (usually non-enhancing) and CMV (usually periventricular/ventriculitis), looking more like Toxoplasmosis or Lymphoma. If the diagnosis were PML (based on astrocytes), no antiviral listed is effective (treatment is ART). If the diagnosis is CMV (as keyed), the stem contains incorrect pathology ('bizarre astrocytes') and the treatment logic is flawed: Ganciclovir (A) is the standard first-line therapy. Selecting Foscarnet (B) requires assuming resistance without evidence (e.g., prior exposure), which is not standard of care. The item conflates features of PML, CMV, and Toxo, making it unsolvable.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically inaccurate and logically invalid due to contradictory clinical and histopathological findings. The vignette describes a patient with CD4 180 cells/μL (typically too high for CMV encephalitis, which usually occurs at <50 cells/μL) and 'bizarre astrocytes' on biopsy. 'Bizarre astrocytes' are the classic histopathological hallmark of Progressive Multifocal Leukoencephalopathy (PML), not CMV. While 'intranuclear inclusions' occur in both, the specific mention of bizarre astrocytes strongly points to PML. However, the MRI showing 'ring-enhancing lesions' is atypical for both PML (usually non-enhancing) and CMV (usually periventricular/ventriculitis), looking more like Toxoplasmosis or Lymphoma. If the diagnosis were PML (based on astrocytes), no antiviral listed is effective (treatment is ART). If the diagnosis is CMV (as keyed), the stem contains incorrect pathology ('bizarre astrocytes') and the treatment logic is flawed: Ganciclovir (A) is the standard first-line therapy. Selecting Foscarnet (B) requires assuming resistance without evidence (e.g., prior exposure), which is not standard of care. The item conflates features of PML, CMV, and Toxo, making it unsolvable.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}]